Deninger et al., in a pilot study, showed interesting results with the v-raf murine sarcoma viral oncogene homolog B1 (best known as BRAF) inhibitor combination, where they observed that seven out of thirty-five patients had an objective therapeutic response, and two of them had a sustaining response that lasted up to three years in metastatic melanoma [29] or with anticytotoxic T lymphocyte-associated molecule-4 (CTLA-4) drug ipilimumab in high-risk, locally/regionally advanced melanoma [30]. Here, BRAF is linked to melanoma.